z-logo
open-access-imgOpen Access
Generation of a Protective T-Cell Response Following Coronavirus Infection of the Central Nervous System Is Not Dependent on IL-12/23 Signaling
Author(s) -
Katherine S. Held,
William G. Glass,
Yevgeniya Orlovsky,
Kimberly Shamberger,
Ted Petley,
Patrick Branigan,
Jill M. Carton,
Heena Beck,
Mark R. Cunningham,
Jacqueline Benson,
Thomas E. Lane
Publication year - 2008
Publication title -
viral immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.777
H-Index - 61
eISSN - 1557-8976
pISSN - 0882-8245
DOI - 10.1089/vim.2008.0014
Subject(s) - central nervous system , coronavirus , neuroscience , biology , signal transduction , immunology , neuroinflammation , virology , medicine , covid-19 , inflammation , microbiology and biotechnology , disease , pathology , infectious disease (medical specialty)
The functional role of IL-12 and IL-23 in host defense and disease following viral infection of the CNS was determined. Instillation of mouse hepatitis virus (MHV, a positive-strand RNA virus) into the CNS of mice results in acute encephalitis followed by a chronic immune-mediated demyelinating disease. Antibody-mediated blocking of either IL-23 (anti-IL-23p19) or IL-12 and IL-23 (anti-IL-12/23p40) signaling did not mute T-cell trafficking into the CNS or antiviral effector responses and mice were able to control viral replication within the brain. Therapeutic administration of either anti-IL-23p19 or anti-IL-12/23p40 to mice with viral-induced demyelination did not attenuate T-cell or macrophage infiltration into the CNS nor improve clinical disease or diminish white matter damage. In contrast, treatment of mice with anti-IL-12/23p40 or anti-IL-23p19 resulted in inhibition of the autoimmune model of demyelination, experimental autoimmune encephalomyelitis (EAE). These data indicate that (1) IL-12 and IL-23 signaling are dispensable in generating a protective T-cell response following CNS infection with MHV, and (2) IL-12 and IL-23 do not contribute to demyelination in a model independent of autoimmune T-cell-mediated pathology. Therefore, therapeutic targeting of IL-12 and/or IL-23 for the treatment of autoimmune diseases may offer unique advantages by reducing disease severity without muting protective responses following viral infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom